Director at Genenta (NASDAQ: GNTA) receives 20,000 stock options grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Genenta Science S.p.A. director Giacomoantonio Paracchi reported a compensation-related grant of stock options. On March 30, 2026, he was awarded options covering 20,000 American Depositary Shares at an exercise price of $0.63 per share, expiring on December 31, 2035.

The options vest in equal monthly installments over one year beginning March 30, 2026, aligning the award with ongoing service. Following this grant, Paracchi holds 20,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider PARACCHI GIACOMOANTONIO

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	20,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 20,000 shares (Direct)

Footnotes (1)

[object Object]

Key Figures

Stock options granted: 20,000 options Underlying ADS: 20,000 American Depositary Shares Exercise price: $0.63 per share +3 more

6 metrics

Stock options granted 20,000 options Grant on March 30, 2026

Underlying ADS 20,000 American Depositary Shares Underlying security for options

Exercise price $0.63 per share Conversion or exercise price of options

Expiration date December 31, 2035 Option term end

Total options after grant 20,000 options Holdings following transaction

Vesting period 1 year Equal monthly vesting beginning March 30, 2026

Key Terms

Stock Option (right to buy), American Depositary Shares, Grant, award, or other acquisition, vest in equal monthly installments, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

American Depositary Shares financial

"underlying_security_title: "American Depositary Shares""

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

vest in equal monthly installments financial

"The stock options vest in equal monthly installments over one year"

expiration date financial

"expiration_date: "2035-12-31T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Form 4 Insider Transactions: What Each Field Means →

04/01/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PARACCHI GIACOMOANTONIO

(Last)

(First)

(Middle)

VIA REPUBBLICA 17

(Street)

NOVATE MILANESE

20026

(City)

(State)

(Zip)

ITALY

(Country)

2. Issuer Name and Ticker or Trading Symbol
Genenta Science S.p.A. [ GNTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$0.63	03/30/2026		A		20,000		⁽¹⁾	12/31/2035	American Depositary Shares	20,000	$0	20,000	D

Explanation of Responses:

1. The stock options vest in equal monthly installments over one year beginning March 30, 2026.

	/s/ Giacomoantonio Paracchi	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did GNTA director Giacomoantonio Paracchi report?

He reported a grant of stock options for 20,000 American Depositary Shares. The options are a compensation-related award, not an open-market purchase or sale, and were granted at a fixed exercise price with a long-dated expiration.

How many Genenta (GNTA) stock options were granted in this Form 4?

The filing shows a grant of stock options covering 20,000 American Depositary Shares. These options give the director the right to buy that number of ADS at a preset exercise price if and when they vest.

What is the exercise price and expiration date of the GNTA options granted?

The stock options have an exercise price of $0.63 per American Depositary Share and expire on December 31, 2035. This long-term horizon is typical for equity incentives designed to align a director’s interests with company performance.

How do the newly granted GNTA stock options vest over time?

According to the footnote, the 20,000 stock options vest in equal monthly installments over one year beginning March 30, 2026. This schedule ties the award to continued service, delivering portions of the grant gradually rather than all at once.

Did the GNTA director buy or sell shares on the open market in this filing?

No open-market buy or sell is reported. The Form 4 reflects a grant or award acquisition of stock options, meaning the director received derivative rights to shares as compensation instead of trading existing stock in the market.

What are the director’s stock option holdings after this GNTA grant?

After this transaction, the director holds 20,000 stock options directly. These options are tied to American Depositary Shares, have a $0.63 exercise price, and will be exercisable only as they vest over the specified one-year period.